Funding for Programs
Promiliad has been exceptionally successful in receiving highly competitive awards from the National Institutes of Health for our antibiotic development programs. To date we have been awarded multiple phase I and phase II SBIR/STTR awards, totaling over $6 million in non-dilutive funds.
The University Of Montana
2020 Single application
thixotropic antibiotic delivery
systems for Otitis externa
The University Of Montana
2019 Novel antibacterial
agents derived from
natural products
The University Of Montana
2018 Single application
thixotropic antibiotic delivery
systems for Otitis externa
The University Of Montana
2016 Novel antibacterial
agents derived from
natural products
–
2013 Development of stable
isosteres of dihydrofolate
reductase inhibitors as
antibacterial agents
The University of Connecticut
2010 Potent antifolates as
new therapeutics for MRSA
The Ohio State University
2009 The identification
of novel negative allosteric
modulators of the
nicotinic receptor
The University of Connecticut
2009 New antibiotics
targeting fatty acid
biosynthesis
Ohio University
2008 Isoindolinones as
antibacterial agents
Dartmouth College
2006 Natural feedstocks
for diversity-oriented
synthesis
Dartmouth College
2006 Potent and selective
DHFR inhibitors for
treating cryptosporidiosis
Ohio University
2005 Fermentation initiated
antibiotic syntheses
University of Florida
2004 Natural feedstocks
for diversity-oriented
synthesis